E.E. Geduld’s Seres Therapeutics MCRB Stock Holding History

E.E. Geduld’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$149K	Sell	750 -500	-40%	-$109K	0.08%	95
2016 Q3	$307K	Buy	+1,250	New	+$439K	0.31%	59
2015 Q3	–	Sell	-250	Closed	-$208K	–	248
2015 Q2	$208K	Buy	+250	New	+$218K	0.13%	171

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

E.E. Geduld's MCRB Position: Q4 2016 in Review

E.E. Geduld reduced its Seres Therapeutics (MCRB) stake by 40% in Q4 2016, selling an estimated $109K and leaving 750 shares worth $149K. The position accounts for 0.08% of the portfolio, ranked #95.

E.E. Geduld first reported a position in MCRB in Q2 2015 and has held it in 3 quarters since. The position peaked at $307K in Q3 2016. 89 funds tracked by Wall St. Rank hold MCRB as of Q4 2016.

E.E. Geduld held 750 shares of Seres Therapeutics worth $149K as of Q4 2016.
E.E. Geduld sold 500 Seres Therapeutics shares in Q4 2016, an estimated $109K.
Seres Therapeutics made up 0.08% of E.E. Geduld's portfolio in Q4 2016, its #95 holding.
E.E. Geduld first reported a position in Seres Therapeutics in Q2 2015 and has held it in 3 quarters since.
E.E. Geduld's Seres Therapeutics position peaked at $307K in Q3 2016.
89 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2016.

Based on E.E. Geduld's 13F filing for Q4 2016, filed 8 Feb 2017.